logo
A Loved One was Diagnosed With Dementia. Now What?

A Loved One was Diagnosed With Dementia. Now What?

New York Times25-06-2025
About four years ago, Madhavi Phadke, a philanthropy director in Westford, Mass., noticed her mother, Chanda Bhawalkar, was withdrawing. Ms. Bhawalkar had been an avid reader and talented cook who walked daily and regularly texted with her friends back home in Maharashtra, India. But in her late 70s, she began spending more time alone in her room and seemed aloof and often bored, Ms. Phadke said. She became agitated when visitors dropped by, a surprising response from someone who had always maintained a vibrant social life.
At first, Ms. Phadke thought these changes were just normal signs of aging, but as things got worse, she took her mother for a medical evaluation. About two years ago, Ms. Bhawalkar was diagnosed with Alzheimer's disease.
It gave Ms. Phadke clarity, but also feelings of deep sadness and helplessness, she said. 'It's almost like today's going to be the best day for the rest of her life,' she remembered thinking. But she also wanted to 'make the most of what we can' with her mother's remaining time.
It's difficult to know how to proceed when a family member is diagnosed with dementia. Clinicians suggest sorting out logistics early on: appointing a trusted person to make medical decisions on the family member's behalf, planning future care and writing financial directives. But you also have to prepare for the emotional weight of watching a loved one lose pieces of themselves.
'It's the mental equivalent of death by a thousand paper cuts,' said Don Siegel, of Silver Spring, Md., whose wife, Bette, died in 2024 after several years with Lewy body dementia. Families are 'left with someone you can't recognize, except in very brief moments.'
The New York Times asked dementia specialists and seven families who have faced the disease to share advice for moving forward after a diagnosis.
Want all of The Times? Subscribe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse
DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse

Yahoo

time3 hours ago

  • Yahoo

DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse

Poisoned Cannabis, Zero DEA Oversight The DEA's mission statement is a sham under Thomas Prevoznik's watch. Americans are being poisoned by untested state cannabis operators while terminal patients are denied potential cures. WASHINGTON, D.C. / / July 6, 2025 / The Drug Enforcement Administration (DEA) exists to "prevent, detect, and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs". Yet under the leadership of Deputy Administrator Thomas Prevoznik, the DEA's Diversion Control Division has catastrophically failed this mission. Instead of protecting public health, the agency has allowed contaminated cannabis to flood state markets-poisoning consumers-while simultaneously blocking federally compliant pharmaceutical research that could save lives. This is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice. 1. DEA's Mission Failure: Poisoned Cannabis, Zero Oversight The Massachusetts Scandal: A Case Study in Regulatory Collapse In Massachusetts, Assured Testing Laboratories-a facility responsible for testing 25% of the state's cannabis-was caught falsifying safety reports, concealing contamination, and approving products that should have failed for yeast, mold, and microbial toxins. Thousands of tainted products reached consumers, yet the DEA: Took no enforcement action Issued no national recall Failed to intervene despite its mandate to prevent diversion and ensure safety. This is not an isolated incident. Across the U.S., unregulated cannabis markets operate like the "Wild West"-with no federal quality control, no uniform safety standards, and no accountability. The DEA, under Prevoznik, has abdicated its duty, leaving Americans exposed to dangerous products while offering no recourse. 2. Blocking Medical Breakthroughs: The DEA's War on Science While turning a blind eye to contaminated street cannabis, the DEA has actively obstructed federally approved pharmaceutical research. MMJ BioPharma, a company developing cannabis-based treatments for Huntington's Disease and Multiple Sclerosis, has faced seven years of bureaucratic sabotage despite: Holding FDA Investigational New Drug (IND) approvals Securing Orphan Drug Designation for Huntington's therapy Passing DEA security inspections. Yet, Prevoznik's division refuses to grant MMJ a bulk manufacturing license, citing a retroactive "Bona Fide Supply Agreement" (BFSA) requirement that creates an impossible Catch-22: No supplier will sign a contract without DEA approval. DEA won't approve without a signed contract. This obstruction is not just regulatory failure-it's deliberate stonewalling. As MMJ's legal filings reveal, DEA Administrative Law Judges (ALJs) operate in a structurally biased system, where registrants win only 20-25% of cases, and the DEA overturns nearly all pro-registrant rulings. 3. The Human Cost: Patients Suffer While Illicit Markets Thrive The DEA's hypocrisy is staggering: Patients with epilepsy, cancer, and neurological disorders are denied access to standardized, pharmaceutical-grade cannabis112. Meanwhile, unregulated THC products-laced with pesticides, mold, and heavy metals-flood the market, making consumers sick 15. Prevoznik's DEA has created the worst of both worlds:No protection for consumers from tainted pathway for research into life-saving medicines. 4. Time for Accountability: Fire Prevoznik, Overhaul the DEA The solution is clear: Remove Thomas Prevoznik for gross negligence and regulatory malpractice. Transfer cannabis oversight to the FDA/NIH, where science-not stigma-guides policy. Investigate DEA's Diversion Control Division for systemic bias and corruption. As MMJ BioPharma CEO Duane Boise stated: "The DEA's Diversion Control Division, under Prevoznik's leadership, has failed to protect the public, failed to uphold science, and failed to meet even the most basic standards of competence." Fire Thomas Prevoznik: A Call to Action The DEA's mission statement is a sham under Prevoznik's watch. Americans are being poisoned by untested cannabis while terminal patients are denied potential cures. Congress must intervene, the courts must act, and the public must demand accountability. Enough is enough. It's time to end the DEA's obstructionism and put public health over bureaucracy. MMJ is Represented by Attorney Megan Sheahan and Associates CONTACT:Madison Hiseymedia@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's
Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's

Yahoo

time3 hours ago

  • Yahoo

Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's

Stores of glucose in the brain could play a much more significant role in the pathological degeneration of neurons than scientists realized, opening the way to new treatments for conditions like Alzheimer's disease. Alzheimer's is a tauopathy; a condition characterized by harmful build-ups of tau proteins inside neurons. It's not clear, however, if these build-ups are a cause or a consequence of the disease. A new study now adds important detail by revealing significant interactions between tau and glucose in its stored form of glycogen. Led by a team from the Buck Institute for Research on Aging in the US, the research sheds new light on the functions of glycogen in the brain. Before now, it's only been regarded as an energy backup for the liver and the muscles. "This new study challenges that view, and it does so with striking implications," says molecular biologist Pankaj Kapahi, from the Buck Institute. "Stored glycogen doesn't just sit there in the brain, it is involved in pathology." Related: Building on links previously found between glycogen and neurodegeneration, the researchers spotted evidence of excessive glycogen levels both in tauopathy models created in fruit flies (Drosophila melanogaster) and in the brain cells of people with Alzheimer's. Further analysis revealed a key mechanism at play: tau proteins interrupt the normal breakdown and use of glycogen in the brain, adding to the dangerous build-up of both tau and glycogen, as well as lowering protective neuron defense barriers. Crucial to this interaction is the activity of glycogen phosphorylase or GlyP, the main enzyme tasked with turning glycogen into a fuel the body can use. When the researchers boosted GlyP production in fruit flies, glycogen stores were utilized once more, helping to fight back against cell damage. "By increasing GlyP activity, the brain cells could better detoxify harmful reactive oxygen species, thereby reducing damage and even extending the lifespan of tauopathy model flies," says Buck Institute biologist Sudipta Bar. The team wondered if a restricted diet – already associated with better brain health – would help. When fruit flies affected by tauopathy were put on a low-protein diet, they lived longer and showed reduced brain damage, suggesting that the metabolic shift prompted by dieting can help boost GlyP. It's a notable set of findings, not least because it suggests a way that glycogen and tau aggregation could be tackled in the brain. The researchers also developed a drug based around the 8-Br-cAMP molecule to mimic the effects of dietary restriction, which had similar effects on flies in experiments. The work might even tie into research involving GLP-1 receptor agonists such as Ozempic, designed to manage diabetes and reduce weight loss, but also now showing promise for protecting against dementia. That might be because these drugs interact with one of glycogen's pathways, the researchers suggest. "By discovering how neurons manage sugar, we may have unearthed a novel therapeutic strategy: one that targets the cell's inner chemistry to fight age-related decline," says Kapahi. "As we continue to age as a society, findings like these offer hope that better understanding – and perhaps rebalancing – our brain's hidden sugar code could unlock powerful tools for combating dementia." The research has been published in Nature Metabolism. Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer FDA Issues Warning Over Dangerous 'Gas Station Heroin' Substance Mysterious Leprosy Pathogen Has Lurked in The Americas For 4,000 Years

DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse
DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse

Associated Press

time3 hours ago

  • Associated Press

DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse

Poisoned Cannabis, Zero DEA Oversight The DEA's mission statement is a sham under Thomas Prevoznik's watch. Americans are being poisoned by untested state cannabis operators while terminal patients are denied potential cures. WASHINGTON, D.C. / ACCESS Newswire / July 6, 2025 / The Drug Enforcement Administration (DEA) exists to 'prevent, detect, and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs ". Yet under the leadership of Deputy Administrator Thomas Prevoznik, the DEA's Diversion Control Division has catastrophically failed this mission. Instead of protecting public health, the agency has allowed contaminated cannabis to flood state markets-poisoning consumers-while simultaneously blocking federally compliant pharmaceutical research that could save lives. This is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice. 1. DEA's Mission Failure: Poisoned Cannabis, Zero Oversight The Massachusetts Scandal: A Case Study in Regulatory Collapse In Massachusetts, Assured Testing Laboratories-a facility responsible for testing 25% of the state's cannabis-was caught falsifying safety reports, concealing contamination, and approving products that should have failed for yeast, mold, and microbial toxins. Thousands of tainted products reached consumers, yet the DEA: This is not an isolated incident. Across the U.S., unregulated cannabis markets operate like the 'Wild West"-with no federal quality control, no uniform safety standards, and no accountability. The DEA, under Prevoznik, has abdicated its duty, leaving Americans exposed to dangerous products while offering no recourse. 2. Blocking Medical Breakthroughs: The DEA's War on Science While turning a blind eye to contaminated street cannabis, the DEA has actively obstructed federally approved pharmaceutical research. MMJ BioPharma, a company developing cannabis-based treatments for Huntington's Disease and Multiple Sclerosis, has faced seven years of bureaucratic sabotage despite: Yet, Prevoznik's division refuses to grant MMJ a bulk manufacturing license, citing a retroactive 'Bona Fide Supply Agreement' (BFSA) requirement that creates an impossible Catch-22: This obstruction is not just regulatory failure-it's deliberate stonewalling. As MMJ's legal filings reveal, DEA Administrative Law Judges (ALJs) operate in a structurally biased system, where registrants win only 20-25% of cases, and the DEA overturns nearly all pro-registrant rulings. 3. The Human Cost: Patients Suffer While Illicit Markets Thrive The DEA's hypocrisy is staggering: Prevoznik's DEA has created the worst of both worlds: No protection for consumers from tainted products. No pathway for research into life-saving medicines. 4. Time for Accountability: Fire Prevoznik, Overhaul the DEA The solution is clear: As MMJ BioPharma CEO Duane Boise stated: 'The DEA's Diversion Control Division, under Prevoznik's leadership, has failed to protect the public, failed to uphold science, and failed to meet even the most basic standards of competence.' Fire Thomas Prevoznik: A Call to Action The DEA's mission statement is a sham under Prevoznik's watch. Americans are being poisoned by untested cannabis while terminal patients are denied potential cures. Congress must intervene, the courts must act, and the public must demand accountability. Enough is enough. It's time to end the DEA's obstructionism and put public health over bureaucracy. MMJ is Represented by Attorney Megan Sheahan and Associates CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store